PCNU in the treatment of recurrent medulloblastoma and ependymoma--a POG Study

J Neurooncol. 1986;3(4):341-2. doi: 10.1007/BF00165583.

Abstract

Seventeen children with recurrent medulloblastoma and ependymoma received PCNU (100 mg/m2) in a Phase II trial. Response was evaluated by CAT scan. There were no responses. Administration of PCNU was associated with significant thrombocytopenia.

MeSH terms

  • Adolescent
  • Brain Neoplasms / drug therapy*
  • Child
  • Child, Preschool
  • Drug Evaluation
  • Ependymoma / drug therapy*
  • Humans
  • Medulloblastoma / drug therapy*
  • Neoplasm Recurrence, Local / drug therapy
  • Nitrosourea Compounds / adverse effects
  • Nitrosourea Compounds / therapeutic use*
  • Thrombocytopenia / chemically induced
  • Tomography, X-Ray Computed

Substances

  • Nitrosourea Compounds
  • 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidinyl)-1-nitrosourea